Technical Analysis for REPL - Replimune Group, Inc.

Grade Last Price % Change Price Change
D 16.50 -0.60% -0.10
REPL closed down 0.6 percent on Thursday, September 28, 2023, on 1.47 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Outside Day Range Expansion -0.60%
Wide Bands Range Expansion -0.60%
Oversold Stochastic Weakness -0.60%
Wide Bands Range Expansion 3.38%
Down 3 Days in a Row Weakness 3.38%
Oversold Stochastic Weakness 3.38%
Wide Bands Range Expansion 2.17%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 12 hours ago
60 Minute Opening Range Breakdown about 12 hours ago
Down 2 % about 12 hours ago
10 DMA Resistance about 12 hours ago
1.5x Volume Pace about 12 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapy Products Oncolytic Virus Experimental Cancer Treatments Transgene Sa Akseli Hemminki Rp1

Is REPL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 29.5229
52 Week Low 15.51
Average Volume 536,148
200-Day Moving Average 21.41
50-Day Moving Average 19.32
20-Day Moving Average 18.23
10-Day Moving Average 16.91
Average True Range 0.86
RSI (14) 32.43
ADX 38.09
+DI 8.74
-DI 28.46
Chandelier Exit (Long, 3 ATRs) 18.73
Chandelier Exit (Short, 3 ATRs) 18.22
Upper Bollinger Bands 21.14
Lower Bollinger Band 15.32
Percent B (%b) 0.2
BandWidth 31.93
MACD Line -0.99
MACD Signal Line -0.80
MACD Histogram -0.1836
Fundamentals Value
Market Cap 758.38 Million
Num Shares 46 Million
EPS -1.01
Price-to-Earnings (P/E) Ratio -16.27
Price-to-Sales 0.00
Price-to-Book 7.94
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.88
Resistance 3 (R3) 17.86 17.38 17.65
Resistance 2 (R2) 17.38 17.03 17.39 17.57
Resistance 1 (R1) 16.94 16.81 16.70 16.96 17.50
Pivot Point 16.46 16.46 16.34 16.47 16.46
Support 1 (S1) 16.02 16.11 15.78 16.04 15.50
Support 2 (S2) 15.54 15.89 15.55 15.43
Support 3 (S3) 15.10 15.54 15.35
Support 4 (S4) 15.12